Gilman Hill Asset Management LLC Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

Gilman Hill Asset Management LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 18.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 330,904 shares of the biopharmaceutical company's stock after purchasing an additional 51,605 shares during the period. Pfizer comprises 1.5% of Gilman Hill Asset Management LLC's investment portfolio, making the stock its 15th largest holding. Gilman Hill Asset Management LLC's holdings in Pfizer were worth $8,779,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Thrivent Financial for Lutherans boosted its holdings in Pfizer by 2.8% in the second quarter. Thrivent Financial for Lutherans now owns 739,236 shares of the biopharmaceutical company's stock valued at $20,684,000 after acquiring an additional 20,140 shares during the last quarter. Sompo Asset Management Co. Ltd. boosted its stake in shares of Pfizer by 15.1% in the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 22,470 shares of the biopharmaceutical company's stock valued at $629,000 after purchasing an additional 2,950 shares during the last quarter. Schwerin Boyle Capital Management Inc. raised its stake in Pfizer by 8.2% during the second quarter. Schwerin Boyle Capital Management Inc. now owns 775,125 shares of the biopharmaceutical company's stock worth $21,688,000 after buying an additional 58,850 shares during the last quarter. Kowal Investment Group LLC lifted its holdings in Pfizer by 10.3% in the second quarter. Kowal Investment Group LLC now owns 18,834 shares of the biopharmaceutical company's stock valued at $527,000 after buying an additional 1,757 shares during the period. Finally, ProShare Advisors LLC lifted its holdings in Pfizer by 7.3% in the second quarter. ProShare Advisors LLC now owns 845,638 shares of the biopharmaceutical company's stock valued at $23,661,000 after buying an additional 57,825 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.19 during midday trading on Monday, reaching $26.30. The company's stock had a trading volume of 35,146,711 shares, compared to its average volume of 35,869,448. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. The firm has a 50 day moving average price of $26.08 and a 200-day moving average price of $27.99. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio is currently 227.03%.

Analyst Ratings Changes

Several research analysts have recently weighed in on PFE shares. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. Cantor Fitzgerald reissued an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Evercore ISI upgraded Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. StockNews.com lowered shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Finally, Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a "market perform" rating and a $32.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business's stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company's stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.